GENB

Generate Biomedicines, Inc. Common Stock

17.12

USD

+1.44

+9.18%

Sep 17, 15:59 UTC -4

Closed

After-Market

17.25

+0.13

+0.76%

GENB Earnings Reports

Positive Surprise Ratio

GENB beat 0 of 2 last estimates.

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Generate Biomedicines, Inc. Common Stock earnings per share and revenue

On Aug 06, 2026, GENB reported earnings of -0.52 USD per share (EPS) for Q2 26, missing the estimate of -0.50 USD, resulting in a -2.79% surprise. Revenue reached 6.31 million, compared to an expected 6.76 million, with a -6.56% difference. The market reacted with a -4.14% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

enGene Therapeutics Inc. Common Stock

Report Date

Sep 08, 2026 For Q3 26

Estimate

-$0.43

Actual

-$0.47

Surprise

-7.16%

Anixa Biosciences, Inc.

Report Date

Sep 09, 2026 For Q3 26

Estimate

-$0.08

Actual

-$0.08

Surprise

+8.78%

Alzamend Neuro, Inc. Common Stock

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.57

Actual

-$0.68

Surprise

-19.05%

FAQ

What were Generate Biomedicines, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Generate Biomedicines, Inc. Common Stock reported EPS of -$0.52, missing estimates by -2.79%, and revenue of $6.31M, -6.56% below expectations.

How did the market react to Generate Biomedicines, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -4.14%, changed from $14.49 before the earnings release to $13.89 the day after.

When is Generate Biomedicines, Inc. Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Generate Biomedicines, Inc. Common Stock's next earnings report?

Based on -- analysts, Generate Biomedicines, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.